Good morning! Between October 1 and October 4, there were 50 new positions posted on the ACS Careers website. Of them, 33 (66%) are academically connected and 1 is from our friends at Kelly Scientific Resources.
Enjoy the kebab: Ideal Innovations, Inc. is looking for B.S. chemists to be explosive chemical analysts; 2 years experience with GC/MS, FTIR, XRD and XRF is desired. Don't worry, you'll be fine... in your compound in Afghanistan. (No, really.) This has got to pay incredible money.
Stumptown is better: Kineta is "a Seattle-based biotech company dedicated to the discovery and development of products to treat infectious and autoimmune/inflammatory diseases." They're looking for an experienced Ph.D. medicinal chemist to be a med-chem group leader; "previous analytical methods development and assay optimization skills are desirable." (Because you wouldn't have enough to do.)
Super-multi-nanodisciplinary scientist needed: Check this out. Ventana Medical Systems is looking for a M.S./Ph.D. chemist and here's their list of things they want: "Expertise in Organic, Bio-organic or Material Scientist in the area of nanotechnology particularly self-assembly, nanoparticle synthesis, synthesis of organic compounds, novel bioconjugation methods, biological molecules i.e. antibodies and other proteins as well as nucleic acids, characterization of such conjugates, development of bioassays leading to the simultaneous detection of various proteins over-expressed in cancer (Immunohistochemistry IHC) as well as genes (in-situ hybridization ISH) assays highly desireable." Okay, dudes -- this is like 3 jobs rolled into one.
RTP: Novan is looking for a Ph.D. analytical chemist with experience in pharmaceutics for QA/QC drug development work. Qualifications include "[s]trong work ethic and ability to meet challenging deadlines"; good luck with that.
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20